Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.34 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.34 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.34 |
| ▸ | CCR1 | P32246 | 2/20 | 0.34 |
| ▸ | EBP | Q15125 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14731171 | 0.84 | FLT3 (0.35) | — | |
| SCHEMBL14720799 | 0.82 | HRH3 (0.32) | HRH3CCR1 | |
| SCHEMBL14720741 | 0.81 | OPRM1 (0.44) | SIGMAR1 | |
| SCHEMBL14721393 | 0.78 | HRH3 (0.36) | HRH3MEN1KMT2ACCR1 | |
| SCHEMBL14720519 | 0.78 | HRH3 (0.34) | HRH3CCR1 | |
| SCHEMBL14721083 | 0.77 | OPRM1 (0.34) | HRH3 | |
| SCHEMBL14721517 | 0.76 | HRH3 (0.32) | HRH3CCR1 | |
| SCHEMBL14720611 | 0.76 | HRH3 (0.32) | HRH3CCR1 | |
| SCHEMBL14720610 | 0.76 | HRH3 (0.32) | HRH3CCR1 | |
| SCHEMBL14721390 | 0.74 | DRD1 (0.33) | HRH3CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013027001-A1 | COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |